Title : 2018 Year in Review - Hepatitis Newsletters, Headlines & Updates
link : 2018 Year in Review - Hepatitis Newsletters, Headlines & Updates
2018 Year in Review - Hepatitis Newsletters, Headlines & Updates
Welcome folks, for a recap of this year's HCV accomplishments check out the following newsletter, blog and journal updates.
2018 - January Newsletters
Weekly Bull
Read The Latest Issue: Weekly Bull
Another year has come and gone; and what a year it has been! Again, major breakthroughs in HCV treatment made their way to the public, with new options for re-treatment, shorter treatment and ease of treatment. The new pan-genotypic treatments require less testing and some of the newer drugs have drastically lower prices!
Another year has come and gone; and what a year it has been! Again, major breakthroughs in HCV treatment made their way to the public, with new options for re-treatment, shorter treatment and ease of treatment. The new pan-genotypic treatments require less testing and some of the newer drugs have drastically lower prices!
This month you're in for treat, featured in HCV Advocates 20th Anniversary Newsletter is a look back at the early days of HCV, and the people who made the Hepatitis C Support Project possible.
Here is an overview:
By Alan FranciscusIn 1996, shortly after a diagnosis of HCV, I started the Hepatitis C Support Project (HCSP). The HCV Advocate newsletter, our website and our national training program came later. Our humble beginnings started with support groups (HCV and HIV/HCV coinfected) and a local helpline. I also had one-on-one counseling in my home (I had no boundaries!). Additionally, I started to develop educational materials—the first one was our HCV Information Packet
By Lucinda K. Porter, RN
When the first HCV Advocate was published, hep C treatment was long, tough, and the response rates were low. The only treatment was interferon. It was not pegylated and injections were three times weekly. Ribavirin was not yet in the picture. Now HCV medications can cure just about everyone with a short, tolerable treatment.
When the first HCV Advocate was published, hep C treatment was long, tough, and the response rates were low. The only treatment was interferon. It was not pegylated and injections were three times weekly. Ribavirin was not yet in the picture. Now HCV medications can cure just about everyone with a short, tolerable treatment.
“Many state Medicaid systems have removed restrictions on access to HCV medications based on liver disease severity. Hopefully, in 2018 all the restrictions on disease severity will be removed.”
By Matthew Zielske
We cannot fail to fuel the eradication of this epidemic with heart and inspiration as much as logic and science. We must look back to understand what we missed so that we can see what is in front of us.
British Liver Trust
In Touch e-newsletter January 2018Two studies published in December highlighted that young people are putting themselves at increased risk of developing liver disease. The studies focused on obesity and alcohol – two of the major risk factors for liver disease.
National Viral Hepatitis Roundtable
Read NVHR’s December 2017/January 2018 newsletter to read about NVHR’s 2017 accomplishments, conference recaps, NVHR’s Job Announcement, and more!
In The News
Healio
10 reports from 2017 on liver cancer incidence rates, major risk factors
January 5, 2018
Liver cancer rates continue to increase, prompting researchers to focus on leading causes such as hepatitis C and identifying major risk factors. Recent studies have identified some of these factors to include age, comorbidities and ethnicity.
The following reports focus on the incidence of hepatocellular carcinoma among specific demographics and after HCV therapy with direct-acting antivirals, and the efforts made to improve treatment and aftercare.
January 5, 2018
Liver cancer rates continue to increase, prompting researchers to focus on leading causes such as hepatitis C and identifying major risk factors. Recent studies have identified some of these factors to include age, comorbidities and ethnicity.
The following reports focus on the incidence of hepatocellular carcinoma among specific demographics and after HCV therapy with direct-acting antivirals, and the efforts made to improve treatment and aftercare.
PharmaTimes
How the elimination of HCV in England could become a reality
Dr Andrew Ustianowski
Hepatitis C virus (HCV) infection is a significant public health issue in England, but one which the World Health Organization (WHO) has announced can be eliminated within a generation. New direct-acting antiviral curative treatments have been available in the UK since 2015, which means that theoretically it is possible to meet the WHO target and eliminate a disease which currently is a heavy burden on patients, carers and the health system. However, although England has pledged support for the WHO initiative, without a formal elimination strategy in place it is going to be difficult to meet this aim.
Elizabeth Payne
A key to preventing unintentional overdoses, Yoshida believes, would be limiting sales of acetaminophen to 325 mg tablets, which would mean the end of popular Extra Strength Tylenol, which contains 500 mg of acetaminophen.Clinical Care Options
How Injection Drug Use Affects HCV Treatment
Norah Terrault MD, MPH - 1/3/2018
Here’s my take on why colocalization of HCV treatment with other medical and social services may be ideal for persons who inject drugs.
Norah Terrault MD, MPH - 1/3/2018
Here’s my take on why colocalization of HCV treatment with other medical and social services may be ideal for persons who inject drugs.
Journal Updates
Need for prompt treatment of HCV infection in these special populations (i.e., hemodialysis, liver transplantation, HIV co-infection).
Of Interest
The paradox of HBV evolution as revealed from a 16th century mummy
Of Interest
The paradox of HBV evolution as revealed from a 16th century mummy
On Twitter
The following articles were shared and downloaded by @HenryEChang
Local specialty pharmacy & specialty clinic collaboration assists access to hepatitis C direct-acting antivirals
The effective management of costly DAA therapies seemed to be closely linked to the collaboration among the LSP, specialty clinics, and patients to address insurance barriers.
Hepatocellular carcinoma (HCC) has limited treatment options in patients with advanced stage disease and early detection of HCC through surveillance programs is a key component towards reducing mortality. The current practice guidelines recommend that high-risk cirrhosis patients are screened every six months with ultrasonography but these are done in local hospitals with variable quality leading to disagreement about the benefit of HCC surveillance. The well-established diagnostic biomarkerα-Fetoprotein (AFP) is used widely in screening but the reported performance varies widely across studies. We evaluate two biomarker screening approaches, a six-month risk prediction model and a parametric empirical Bayes (PEB) algorithm, in terms of their ability to improve the likelihood of early detection of HCC compared to current AFP alone when applied prospectively in a future study.
Given the recent approval of the first pan-genotypic chronic hepatitis C virus (HCV) therapy, managed care, health systems, and clinicians will need to evaluate current practices related to essential laboratory assessments used to select therapy. Historically, clinicians and payers required a battery of tests to determine HCV genotype, viral load, degree of fibrosis, and organ function. In light of current and forthcoming approvals of pan-genotypic therapy, clinicians and payers can expect a more competitive marketplace and a downward curve in the price of therapy. Ultimately, this development will lead to the cost of screenings and assessment shaving an increased role in selecting an optimal HCV therapy
CATIE
We asked our readers to vote for their choice of the most important HIV or hepatitis C story of 2017.
HEP Blog
Liver Fibrosis, Cirrhosis and Hepatitis C: The Good News
By Greg Jefferys
One of the questions that keeps coming up is how well the liver can heal itself once the virus is removed from the equation.
By Greg Jefferys
One of the questions that keeps coming up is how well the liver can heal itself once the virus is removed from the equation.
By Greg Jefferys
Treating Hep C with any DAA significantly REDUCES the chance of a person developing liver cancer.
By Connie M. Welch
Having a “when-win” attitude changes your outlook and can help fuel proactive steps toward overcoming your hepatitis C.
Having a “when-win” attitude changes your outlook and can help fuel proactive steps toward overcoming your hepatitis C.
It’s a New Year in Hepatitis C Land
By Lucinda K. Porter, RN
By Lucinda K. Porter, RN
Taking a look back at the hepatitis C landscape over the past 20 years.
Creating a World Free of Hepatitis C
Lucinda Porter
January 4, 2018
Do you ever ask what the best diet is? I don’t mean the best way to lose weight. I am talking about the healthiest way to eat.
HEPATITISC.NET
7 Steps to Cope with Chronic IllnessBy Carleen McGuffey - January 4, 2018
Coping with a chronic illness is not easy. Here are some things that helped me: Assign a spokesperson: When I spent a month in the hospital after complications from a liver biopsy...
Life Before and After Hep C
By Daryl Luster - January 3, 2018
In my effort to think of interesting or insightful things to write about, I am inspired by things I hear from people like you, much more than the scientists, doctors, and other...
What’s your hep C diagnosis story?
By Editorial Team - January 2, 2018
A hep C diagnosis can be overwhelming and difficult to process. You may have a million questions and unsure where to start. Everyone’s experience and road to a diagnosis can different but...
Harvard Health Blog
A new shingles vaccine may be more effective than the existing one and has been FDA approved for people age 50 and older, even if they had been previously vaccinated.
While there are two medications used to treat opioid use disorder that can be prescribed on an outpatient basis, a study comparing them found interesting differences in treatment results.
Healthy You
Increased levels of obesity are driving an epidemic of non-alcoholic fatty liver disease. Understanding, diagnosing and treating this progressive condition are now priorities.
The liver is a resilient organ that's easy to ignore - until something goes wrong. Because of its wide-ranging responsibilities, your healthy liver can come under attack by viruses, toxic substances, contaminants and diseases. However, even when under siege, the liver is very slow to complain. People who have problems with their liver are frequently unaware because they may have few, if any, symptoms. Your liver is such a determined organ that it will continue working even when two thirds of it has been damaged. The Canadian Liver Foundation is bringing liver research to life by sharing what we learn from important research to help Canadians protect their liver health and prevent liver disease in themselves and their loved ones.
How your digestive system works
How your digestive system works
Emma Bryce
Constantly churning inside of you, the digestive system performs a daily marvel: it transforms your food into the vital nutrients that sustain your body and ensure your survival. Emma Bryce traces food’s nine-meter-long, 40-hour journey through the remarkable digestive tract.
Problems and potential with probiotics
Constantly churning inside of you, the digestive system performs a daily marvel: it transforms your food into the vital nutrients that sustain your body and ensure your survival. Emma Bryce traces food’s nine-meter-long, 40-hour journey through the remarkable digestive tract.
Problems and potential with probiotics
Probiotics are becoming more prevalent in both consumer and health care settings, but the excitement is tempered by problems, including how to define what is and what isn't one.
Stay warm, here in Michigan its below zero, hope the sun is shining in your part of the world.
Tina
Stay warm, here in Michigan its below zero, hope the sun is shining in your part of the world.
Thus Article 2018 Year in Review - Hepatitis Newsletters, Headlines & Updates
That's an article 2018 Year in Review - Hepatitis Newsletters, Headlines & Updates This time, hopefully can give benefits to all of you. well, see you in posting other articles.
You are now reading the article 2018 Year in Review - Hepatitis Newsletters, Headlines & Updates with the link address https://theleknews.blogspot.com/2018/01/2018-year-in-review-hepatitis.html
Related Posts :
OUR PAST CREATES US, BUT IT DOESN’T HAVE TO DEFINE US ~ Dawn Walton- HCV/HIV-coinfection - Successful direct acting antiviral (DAA) treatment before and after liver transplantation
Preview Seminars Stages Présentation; A Cathar Speaks ~ JEAN MICHEL Cmdr. Lyur- Maintaining A Standard
- Half of hepatitis C patients with private insurance denied life-saving drugs
0 Response to "2018 Year in Review - Hepatitis Newsletters, Headlines & Updates"
Post a Comment